This story has been updated from a version published Aug. 15 to reflect the fact that Iverson Genetics has not yet selected a testing partner for the WARFARIN trial.
As part of a Sept. 1 program hosted by Morehouse School of Medicine, Georgia Governor Nathan Deal will dedicate the day to personalized medicine awareness.
Morehouse is organizing the Personalized Medicine Awareness Day event in collaboration with Emory University and the Georgia Institute of Technology. These three universities are part of the Atlanta Clinical and Translational Science Institute, a consortium formed in 2007 with funding from the National Institutes of Health.
Separately, Morehouse also received $13.3 million from the NIH last year to develop and maintain a multi-institutional database of minority populations that will contain genetic data among other types of health information.
At the event, Institute of Systems Biology Founder Leroy Hood will deliver a keynote address. Other speakers will include Davide Satcher, director of Morehouse's Satcher Health Leadership Institute; Kenneth Brigham, associate VP of the Predictive Health Institute at Emory University; Valerie Montgomery Rice, Morehouse School of Medicine dean; Elizabeth Ofili, national principal investigator of the Warfarin Adverse Event Reduction for Adults Receiving Genetic Testing at Therapy Initiation, or WARFARIN, study; Roger Simon, director of translational programs in stroke at Morehouse; and David Stephens, VP of Research at Emory's Woodruff Health Sciences Center.
Also participating in Personalized Medicine Awareness Day is Iverson Genetics, a diagnostics company that is collaborating with Morehouse and ACTSI to conduct the 7,000-patient WARFARIN study, which will assess whether adjusting warfarin dosing based on the results of genetic testing reduces patients' chances for experiencing drug-related adverse events. The study is being funded by the Centers for Medicare & Medicaid Services under a "coverage with evidence development scheme" (PGx Reporter 03/09/2011).